Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures (QoQ)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities (QoQ)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin (QoQ)EBIT Margin Growth (1y)EBITDA Margin (QoQ)EBITDA Margin Growth (1y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin (QoQ)EBT Margin Growth (1y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)EPS (Weighted Average and Diluted) Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin (QoQ)FCF Margin Growth (1y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin (QoQ)Net Margin Growth (1y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin (QoQ)Operating Margin Growth (1y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) (QoQ)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Assets Growth (3y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Equity Growth (3y)Return on Equity Growth (5y)Return on Sales (QoQ)Return on Sales Growth (1y)Revenue (QoQ)Revenue Growth (1y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Share-based Compensation Growth (5y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Operating Income Growth (3y) (2022 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 32.96%
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -29.67%
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -50.81%
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 13.47%
7 Evaxion A 64.16 Bn 64.14 Bn - 16.35%
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -12.10%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 55.96%
10 Praxis Precision Medicines 10.11 Bn 9.32 Bn - -40.59%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -40.59%
Dec 31, 2025 -32.78%
Sep 30, 2025 -20.95%
Jun 30, 2025 -7.99%
Mar 31, 2025 -2.77%
Dec 31, 2024 -2.92%
Sep 30, 2024 -8.28%
Jun 30, 2024 -0.91%
Mar 31, 2024 -15.17%
Dec 31, 2023 -2.64%
Sep 30, 2023 -16.31%
Jun 30, 2023 -44.57%
Mar 31, 2023 -65.07%
Dec 31, 2022 -76.85%
Sep 30, 2022 -60.79%